Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-07-04
2006-07-04
Winkler, Ulrike (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C424S184100, C424S185100, C424S188100, C424S202100, C424S204100, C424S208100, C514S04400A, C536S023100, C536S023400
Reexamination Certificate
active
07071322
ABSTRACT:
Oligonucleotide sequences encoding gp120 polypeptides from breakthrough isolates of vaccine trials using MN-rgp120 and the encoded gp120 polypeptides are provided. Use of the gp120 polypeptides from one or more of the isolates in a subunit vaccine, usually together with MN-rgp120, can provide protection against HIV strains that are sufficiently different from the vaccine strain (e.g.; MN-rgp120) that the vaccine does not confer protection against those strains. Antibodies induced by the polypeptides are also provided.
REFERENCES:
patent: 4725669 (1988-02-01), Essex et al.
patent: 5166050 (1992-11-01), Shriver et al.
patent: 5420030 (1995-05-01), Reitz, Jr. et al.
patent: 5576000 (1996-11-01), Reitz, Jr. et al.
patent: 5792459 (1998-08-01), Haigwood
patent: A-33320/89 (1989-11-01), None
patent: 0 187 041 (1986-07-01), None
patent: 0 327 180 (1989-08-01), None
patent: 0 335 635 (1989-10-01), None
patent: 0 339 504 (1989-11-01), None
patent: 0 527 760 (1993-02-01), None
patent: 0 394 386 (1995-09-01), None
patent: 0 187 041 (1996-05-01), None
patent: 0 279 688 (1997-04-01), None
patent: WO 89/12095 (1989-12-01), None
patent: WO 90/02196 (1990-03-01), None
patent: WO 90/03984 (1990-04-01), None
patent: WO 91/04273 (1991-04-01), None
patent: WO 91/13906 (1991-09-01), None
patent: WO 91/15238 (1991-10-01), None
patent: WO 91/15512 (1991-10-01), None
patent: WO 93/20104 (1993-10-01), None
patent: WO 94/28929 (1994-12-01), None
Butini, et al.; Comparative analysis of HIV-specific CTL activity in lymphoid tissue and peripheral blood; J. Cellular Biochemistry; Supp. 18B J 306.
Baltimore, et al.; HIV vaccines: prospects and challenges; Scientific American; pp. 98-103.
Berkower, et al., “A Predominant Group-Specific Neutralizing Epitope of Human Immunodeficiency Virus Type 1 Maps to Residues 342 to 511 of the Envelope Glycoprotein gp120,” Journal of Virology 65 (13), pp. 5983-5990 (Nov. 1991).
Bhat, S. et al., “The Galactosyl Ceramide/Sulfatide Receptor Binding Region of HIV-1 gp120 Maps to Amino Acids 206-275,” AIDS Research and Human Retroviruses 9:2:175-181 (XP002139997) (Feb. 1993).
Cohen; Jitters jeopardize AIDS vaccine trial; Science; vol. 262; pp. 980-981.
Fox; No winners against AIDS; Bio/Technology; vol. 12, p. 128.
Fung, et al., “Identification and Characterization of a Neutralization Site within the Second Variable Region of Human Immunodeficiency Virus Type 1 gp120,” Journal of Virology 66(2), pp. 848-856 (Feb. 1992).
Haynes et al.; Update on the issues of HIV vaccine development; Ann. Med.; vol. 28; pp. 39-41.
Haynes; Scientific and social issues of human immunodeficiency virus vaccine development; Science; vol. 260; pp. 1279-1286.
Ho et al., “Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody,” Proc. Natl. Acad. Sci. USA 88, pp. 8949-8952 (Oct. 1991).
Kahn, et al., Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial. Journal of Infectious Diseases (May 1995) vol. 171, pp. 1343-1350.
McCutchan, et al; Genetic variants of HIV-1 Thailand; AIDS Research and Human Retroviruses; vol. 8, No. 11; pp. 1887-1896.
Moore, et al., “Immunochemical Analysis of the gp120 Surface Glycoprotein of Human Immunodeficiency Virus Type 1: Probing the Structure of the C4 and V4 Domains and the Interaction of the C4 Domain with the V3 Loop,” Journal of Virology 67(8), pp. 4785-4796 (Aug. 1993).
Moore, et al., “Probing the Structure of the Human Immunodeficiency Virus Type 1 Surface Glycoprotein gp120 with a Panel of Eight Monoclonal Antibodies,” Journal of Virology 68(1) pp. 469-484 (Jan. 1994).
Moore, et al., “Probing the Structure of the V2 Domain of Human Immunodeficiency Virus Type 1 Surface Glycoprotein gp120 with a Panel of Eight Monoclonal Antibodies: Human Immune Response to the V1 and V2 Domains,” Journal of Virology 67(10), pp. 6136-6151 (Oct. 1993).
Sirko, et al. Genotype and phenotype characterization of a neutralization-resistant breakthrough population of HIV-1, Virology (1996) pp. 238-242.
Sullivan, et al., “Effect of Amino Acid Changes in the V1/V2 Region of the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein on Subunit Assocation, Syncytium Formation, and Recognition by a Neutralizing Antibody,” Journal of Virology 67(6), pp. 3674-3679 (Jun. 1993).
Zarling, et al.; T-cell responses to human AIDS virus in macaques immunized with recombinant vaccinia viruses; Nature; vol., 323; pp. 344-346.
Allan et al., “Major Glycoprotein Antigens that Induce Antibodies in AIDS Patients are Encoded by HTLV-III,”Science228, pp. 1091-1094 (May 31, 1985).
Anderson et al., “Effect of Dose and Immunization Schedule on Immune Response of Baboons to Recombinant Glycoprotein 120 of HIV-1,”The Journal of Infectious Diseases160(6), pp. 960-969 (Dec. 1989).
Arthur et al., “Challenge of Chimpanzees (Pan troglodytes) Immunized with Human Immunodeficiency Virus Envelope Glycoprotein gp 120,”Journal of Virology63(12), pp. 5046-5053 (Dec. 1989).
Arthur, Larry O., “Serological Responses in Chimpanzees Inoculated With Human Immunodeficiency Virus Glycoprotein (gp120) Subunit Vaccine,”Proc. Natl. Acad. Sci. USA84, pp. 8583-8587 (Dec. 1987).
Barin et al., “Virus Envelope Protein of HTLV-III Represents Major Target Antigen For Antibodies in AIDS Patients,”Science228, pp. 1094-1096 (May 31, 1985).
Barrett et al., “Large-Scale Production and Purification of a Vaccinia Recombinant-Derived HIV-1 gp160 and Analysis of Its Immunogenicity,”AIDS Research And Human Retroviruses5(2), pp. 159-171 (1989).
Berman et al., “Protection from Genital Herpes Simplex Virus Type 2 Infection by Vaccination with Cloned Type 1 Glycoprotein D,”Science227, pp. 1490-1492 (Mar. 1985).
Berman et al., “Human Immunodeficiency Virus Type 1 Challenge of Chimpanzees Immunized with Recombinant Envelope Glycoprotein gp120,”Proc. Natl. Acad. Sci. USA85, pp. 5200-5204 (Jul. 1988).
Berman et al., “Expression and Immunogenicity of the Extracellular Domain of the Human Immunodeficiency Virus Type-1 Envelope Glycoprotein gp160,”Journal of Virology63(8), pp. 3489-3498 (Aug. 1989).
Berman, P., et al., “Protection of Chimpanzees From Infection by HIV-1 After Vaccination with Recombinant Glycoprotein gp120 But Not gp160,”Nature345(6276), pp. 622-625 (Jun. 14, 1990).
Berman, P., et al., “Neutralization of Multiple Laboratory and Clinical Isolates of Human Immunodeficiency Virus Type 1 (HIV-1) by Antisera Raised Against gp120 from the MN Isolate of HIV-1,”Journal of Virology66(7), pp. 4464-4469 (Jul. 1992).
Berman et al., “Genetic and Immunologic Characterization of Viruses Infecting MN-rgp120 Vaccinated Volunteers,”One World, One Hope: XI International Conference on AIDS, 10:3:10 (Jul. 7-12, 1996).
Berman et al., “Genetic and Immunologic Characterization of Viruses Infecting MN-rpg120-Vaccinated Volunteers,” The Journal of Infectious Disease, 176:2:384-397 (Aug. 1997).
Broliden, P., et al., “Identification of Human Neutralization-inducing Regions of the Human Immunodeficiency Virus Type I Envelope Glycoproteins,”Proc. Natl. Acad. Sci. USA89, pp. 461-465 (Jan. 1992).
Bruck, Claudine, et al., “HIV-1 Envelope-elicited Neutralizing Antibody Titres Correlate With Protection and Virus Load In Chimpanzees,”Vaccine12(12), pp. 1141-1148 (1994).
Chakrabarti et al., “Expression of the HTLV-III Envelope Gene by a Recombinant Vaccinia Virus,”Nature320, pp. 535-540 (Apr. 10, 1986).
Clements et al., “The V3 Loops of the HIV-1 and HIV-2 Surface Glycoproteins Contain Proteolytic Cleavage Sites: A Possible Functions in Viral Fusion?”AIDS Research and Human Retroviruses7(1), pp. 3-16 (1991).
Clements,Certificate of
Genentech Inc.
Haliday Emily M.
Quine I.P. Law Group P.C.
Winkler Ulrike
LandOfFree
HIV envelope polynucleotides and immunogenic composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HIV envelope polynucleotides and immunogenic composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV envelope polynucleotides and immunogenic composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3590956